Drugs / TAC01-HER2
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04727151 | Apr 2021 → Dec 2023 | gastroesophageal cancer | Triumvira Immunologics, Inc. | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAC01-HER2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04727151 ↗ |
| Action | Deplete | “TAC T cells recognize the HER2 protein present on the surface of tumor cells, and eradicate them.” NCT04727151 ↗ |
| Modality | Cell therapy | “TAC01-HER2 is a novel cell therapy” NCT04727151 ↗ |
| Route | Intravenous | “Lymphodepletion followed by TAC01-HER2 as a single IV infusion” NCT04727151 ↗ |